Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial

BACKGROUND: Patients with advanced esophageal cancer carry poor prognoses; limited data exist to guide second-line therapy in the metastatic setting. Paclitaxel has been used yet is associated with limited efficacy. There is preclinical evidence of synergy between paclitaxel and cixutumumab, a monoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Stockton, Shannon, Catalano, Paul, Cohen, Steven J, Burtness, Barbara A, Mitchell, Edith P, Dotan, Efrat, Lubner, Sam J, Kumar, Pankaj, Mulcahy, Mary F, Fisher, George A, Crandall, Theodore L, Benson, Al
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485278/
https://www.ncbi.nlm.nih.gov/pubmed/37104870
http://dx.doi.org/10.1093/oncolo/oyad096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485278/
https://www.ncbi.nlm.nih.gov/pubmed/37104870
http://dx.doi.org/10.1093/oncolo/oyad096

Ejemplares similares